Related Experiment Video
Updated: Jun 6, 2026
Measuring Growth and Gene Expression Dynamics of Tumor-Targeted S. Typhimurium Bacteria
Published on: July 6, 2013
Antitumor therapeutic effects of a genetically engineered Salmonella typhimurium harboring TNF-α in mice
Won Suck Yoon1, Yang Seok Chae, Juyeon Hong
1Department of Biotechnology, School of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea.
Abstract:
Although the use of TNF-α in the treatment of cancer is restricted due to its non-specific cytotoxicity and narrow range of applications to different cancers in clinical trials, we investigated a safe anti-cancer drug by the use of engineered bacterial capsule harboring TNF-α. The engineered bacterial capsule was designed to target cancer cells, promote a tumor-suppressive environment, and increase the efficacy of existing cancer treatments, including chemotherapy, radiotherapy, and cell therapy. The engineered bacterial capsule was constructed with Salmonella capsulizing TNF-α protein, which was produced and capsulized by Salmonella to reduce side effects of the protein. This bacterial capsule induced a tumor-suppressive environment through the activation of natural killer cells. Engineered bacterial capsule invaded tumor cells, released TNF-α, and induced apoptosis of tumor cells without apparent side effects. In a murine melanoma model, the bacterial capsule of TNF-α significantly inhibited tumor growth by 80-100% and prolonged the survival of the mice. When tested in combination with chemotherapy (cisplatin), antibiotics, and vaccine, recombinant microbial treatment increased the anti-tumor effects of existing therapies. The anti-tumor effects of the bacterial capsule of TNF-α were also observed in cervical cancer, melanoma, breast cancer, colon cancer, and renal carcinoma. These results suggest that the bacterial capsule of TNF-α is a promising strategy for TNF-α treatment.
Insights
Engineered bacterial capsules carrying tumor necrosis factor-alpha (TNF-α) offer a targeted cancer therapy. This novel approach reduces side effects and enhances existing treatments, showing significant tumor inhibition in preclinical models.
Area of Science:
- Oncology
- Microbiology
- Immunology
Background:
- Tumor necrosis factor-alpha (TNF-α) has limited clinical use in cancer due to toxicity and narrow efficacy.
- Targeted delivery systems are needed to improve TNF-α's therapeutic index for cancer treatment.
Purpose of the Study:
- To develop and evaluate an engineered bacterial capsule system for targeted delivery of TNF-α.
- To assess the safety and efficacy of this system in promoting a tumor-suppressive environment and enhancing anti-cancer therapies.
Main Methods:
- Construction of Salmonella bacterial capsules engineered to encapsulate and release TNF-α protein.
- Evaluation of the bacterial capsule's ability to target cancer cells, activate natural killer cells, and induce tumor cell apoptosis.
- Assessment of anti-tumor efficacy in a murine melanoma model, both as monotherapy and in combination with chemotherapy, antibiotics, and vaccines.
- Testing in various cancer types including cervical cancer, melanoma, breast cancer, colon cancer, and renal carcinoma.
Main Results:
- The engineered bacterial capsule effectively delivered TNF-α, inducing apoptosis in tumor cells with reduced side effects.
- Significant tumor growth inhibition (80-100%) and prolonged survival were observed in a murine melanoma model.
- Combination therapy demonstrated enhanced anti-tumor effects compared to existing treatments.
- Anti-tumor activity was confirmed across multiple cancer types.
Conclusions:
- Engineered bacterial capsules offer a promising, safe, and effective strategy for targeted TNF-α delivery in cancer therapy.
- This approach enhances the efficacy of conventional cancer treatments and warrants further clinical investigation.
